http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2015531397-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P41-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-245 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P41-00 |
| filingDate | 2013-10-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2015-11-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | JP-2015531397-A |
| titleOfInvention | Treatment of vascular disease and its complications |
| abstract | Administration of an antibody that specifically binds IL-1a may cause a major clinical adverse event in a mammalian subject who has undergone or is expected to undergo surgical treatment of a stenotic blood vessel or a major clinical adverse event that occurs in this mammalian subject. Time to reduce the severity of the event and reduce the likelihood of restenosis (or time to restenosis) in a mammalian subject who has undergone or is expected to undergo surgical treatment of a constricted blood vessel Is useful for prolonging). [Selection figure] None |
| priorityDate | 2012-10-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 31.